Home/Pipeline/AT-017

AT-017

Breast Cancer

Not SpecifiedActive

Key Facts

Indication

Breast Cancer

Phase

Not Specified

Status

Active

Company

Asieris Pharmaceuticals

About Asieris Pharmaceuticals

Founded in 2010 and publicly listed in China (688176.SH), Asieris Pharmaceuticals is a global biopharma leader in genitourinary and women's health. Its strategy integrates in-house R&D with global partnerships, supported by advanced technology platforms for drug discovery. The company has achieved significant milestones, including the approval of its first-in-class therapy Cevira® in China and the submission of a Marketing Authorization Application to the European Medicines Agency.

View full company profile

Therapeutic Areas

Urologic Oncology Women's Health Breast and Gynecologic Oncology Autoimmune Diseases Infectious Diseases

Other Breast Cancer Drugs

Drug	Company	Phase	Status
Antifibrotic Therapy Program	MeCo Diagnostics	Pre-clinical	Active
inPROBE for HER2	SDS Optic	Clinical Investigation	Completed (March 2023)
ACT‑BC1	Anthrocell	Preclinical	Active
APA-1000 Breast Thermotherapy System	Medifocus	Phase III	Pivotal Trial Approved (IDE/ITA)
Early‑Detection Breast Cancer Screening	Karkinos Healthcare	Market	Active
Unnamed Breast Cancer Program	Click Therapeutics	Pilot/Phase 2	Active
Lerociclib (Lerocliclib)	Chemogenics BioPharma	Phase 3	Completed Phase 3, awaiting FDA approval
CDK2 inhibitor	Acellera	Pre-clinical	Hit Identification
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Active (subset)
Maveropepimut-S (MVP-S)	BioVaxys	Clinical Evaluation	Active
Cannabics® BRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
Undisclosed	Biossil	Phase 2/3	Active